Wockhardt receives USFDA approval for generic version of Wyeth Zosyn

Wockhardt has received USFDA approval to market generic version of Wyeth’s Zosyn, used for treating bacterial infections, in the American market. Wockhardt Bio AG had filed this abbreviated new drug application (ANDA) in collaboration with Fresinius Kabi, Italy (FKAI) where the product development was completed. The ANDA will be manufactured commercially at FKAI, Mitim, Italy.

Company Profile : Wockhardt Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*